Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Estrone
Drug ID BADD_D00834
Description Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione. Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase.
Indications and Usage For management of perimenopausal and postmenopausal symptoms.
Marketing Status approved
ATC Code G03CA07; G03CC04
DrugBank ID DB00655
KEGG ID D00067
MeSH ID D004970
PubChem ID 5870
TTD Drug ID D00ZFP
NDC Product Code 49452-2795; 0220-2129; 71052-548; 0220-2116; 44132-011; 51927-1709; 44132-003; 63083-1516; 38779-0891; 22552-0022; 51552-0445; 0220-2117
UNII 2DI9HA706A
Synonyms Estrone | Estrone, (8 alpha)-Isomer | Estrone, (9 beta)-Isomer | Wehgen | Folliculin (Hormone) | Kestrone | Unigen | Estrone, (+-)-Isomer | Estrovarin
Chemical Information
Molecular Formula C18H22O2
CAS Registry Number 53-16-7
SMILES CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypocalcaemia14.04.01.004--
Irritability19.04.02.013; 08.01.03.011--
Jaundice cholestatic09.01.01.005--Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Mood altered19.04.02.007--Not Available
Mood swings19.04.03.001--Not Available
Muscle spasms15.05.03.004--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Oedema08.01.07.006; 14.05.06.010--Not Available
Ovarian cancer21.11.01.003; 16.12.04.001--Not Available
Pain08.01.08.004--
Pancreatitis07.18.01.001--
Pruritus23.03.12.001--
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Rash23.03.13.001--Not Available
Tenderness08.01.08.005--Not Available
Tension19.06.02.005--Not Available
Thrombophlebitis24.01.02.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Uterine leiomyoma21.07.02.004; 16.04.02.001--Not Available
Vaginal haemorrhage21.08.01.001; 24.07.03.005--
Vaginal infection21.14.02.002; 11.01.10.002--
Vomiting07.01.07.003--
Vulvovaginal candidiasis21.14.02.003; 11.03.03.005--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Porphyrin metabolism disorder14.14.01.006; 09.01.10.004; 03.08.01.006--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages